411 related articles for article (PubMed ID: 20428688)
41. The in vivo trypanocidal effect of the diterpene 5-epi-icetexone obtained from Salvia gilliesii.
Lozano E; Strauss M; Spina R; Cifuente D; Tonn C; Rivarola HW; Sosa MA
Parasitol Int; 2016 Feb; 65(1):23-26. PubMed ID: 26341064
[TBL] [Abstract][Full Text] [Related]
42. Natural and synthetic naphthoquinones active against Trypanosoma cruzi: an initial step towards new drugs for Chagas disease.
Salas CO; Faúndez M; Morello A; Maya JD; Tapia RA
Curr Med Chem; 2011; 18(1):144-61. PubMed ID: 21110810
[TBL] [Abstract][Full Text] [Related]
43. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
Filardi LS; Brener Z
Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
[TBL] [Abstract][Full Text] [Related]
44. Current trends in the pharmacological management of Chagas disease.
Ribeiro V; Dias N; Paiva T; Hagström-Bex L; Nitz N; Pratesi R; Hecht M
Int J Parasitol Drugs Drug Resist; 2020 Apr; 12():7-17. PubMed ID: 31862616
[TBL] [Abstract][Full Text] [Related]
45. Structural design, synthesis and pharmacological evaluation of thiazoles against Trypanosoma cruzi.
de Oliveira Filho GB; Cardoso MVO; Espíndola JWP; Oliveira E Silva DA; Ferreira RS; Coelho PL; Anjos PSD; Santos ES; Meira CS; Moreira DRM; Soares MBP; Leite ACL
Eur J Med Chem; 2017 Dec; 141():346-361. PubMed ID: 29031078
[TBL] [Abstract][Full Text] [Related]
46. Tackling the challenges of human Chagas disease: A comprehensive review of treatment strategies in the chronic phase and emerging therapeutic approaches.
Ramos LG; de Souza KR; Júnior PAS; Câmara CC; Castelo-Branco FS; Boechat N; Carvalho SA
Acta Trop; 2024 Aug; 256():107264. PubMed ID: 38806090
[TBL] [Abstract][Full Text] [Related]
47. Detection and treatment of Trypanosoma cruzi: a patent review (2011-2015).
Rodriguez JB; Falcone BN; Szajnman SH
Expert Opin Ther Pat; 2016 Sep; 26(9):993-1015. PubMed ID: 27376456
[TBL] [Abstract][Full Text] [Related]
48. In vitro and in vivo studies of the biological activity of novel arylimidamides against Trypanosoma cruzi.
De Araújo JS; Da Silva CF; Batista DG; Da Silva PB; Meuser MB; Aiub CA; da Silva MF; Araújo-Lima CF; Banerjee M; Farahat AA; Stephens CE; Kumar A; Boykin DW; Soeiro MN
Antimicrob Agents Chemother; 2014 Jul; 58(7):4191-5. PubMed ID: 24590476
[TBL] [Abstract][Full Text] [Related]
49. Lead identification to clinical candidate selection: drugs for Chagas disease.
Neitz RJ; Chen S; Supek F; Yeh V; Kellar D; Gut J; Bryant C; Gallardo-Godoy A; Molteni V; Roach SL; Khare S; Stinson M; Chatterjee AK; Robertson S; Renslo AR; Arkin M; Glynne R; McKerrow J; Siqueira-Neto JL
J Biomol Screen; 2015 Jan; 20(1):101-11. PubMed ID: 25281737
[TBL] [Abstract][Full Text] [Related]
50. High throughput screening for anti-Trypanosoma cruzi drug discovery.
Alonso-Padilla J; Rodríguez A
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3259. PubMed ID: 25474364
[TBL] [Abstract][Full Text] [Related]
51. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
[TBL] [Abstract][Full Text] [Related]
52. The effect of memantine, an antagonist of the NMDA glutamate receptor, in in vitro and in vivo infections by Trypanosoma cruzi.
Santos Souza HF; Rocha SC; Damasceno FS; Rapado LN; Pral EMF; Marinho CRF; Silber AM
PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007226. PubMed ID: 31536489
[TBL] [Abstract][Full Text] [Related]
53. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
54. An update on benznidazole for the treatment of patients with Chagas disease.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
[TBL] [Abstract][Full Text] [Related]
55. Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.
Oliveira-Silva JC; Machado-de-Assis GF; Oliveira MT; Paiva NC; Araújo MS; Carneiro CM; Martins-Filho OA; Martins HR; Lana Md
Mem Inst Oswaldo Cruz; 2015 Feb; 110(1):86-94. PubMed ID: 25742267
[TBL] [Abstract][Full Text] [Related]
56. Why hasn't there been more progress in new Chagas disease drug discovery?
Vermelho AB; Rodrigues GC; Supuran CT
Expert Opin Drug Discov; 2020 Feb; 15(2):145-158. PubMed ID: 31670987
[No Abstract] [Full Text] [Related]
57. A critical review on Chagas disease chemotherapy.
Rodriques Coura J; de Castro SL
Mem Inst Oswaldo Cruz; 2002 Jan; 97(1):3-24. PubMed ID: 11992141
[TBL] [Abstract][Full Text] [Related]
58. Time and dose-dependence evaluation of nitroheterocyclic drugs for improving efficacy following Trypanosoma cruzi infection: A pre-clinical study.
Mazzeti AL; Diniz LF; Gonçalves KR; Nascimento AFS; Spósito PAF; Mosqueira VCF; Machado-Coelho GLL; Ribeiro I; Bahia MT
Biochem Pharmacol; 2018 Feb; 148():213-221. PubMed ID: 29309767
[TBL] [Abstract][Full Text] [Related]
59. Synthesis, in vitro and in vivo anti-Trypanosoma cruzi and toxicological activities of nitroaromatic Schiff bases.
Cunha Almeida T; Gonzaga Ribeiro LH; Ferreira Dos Santos LB; da Silva CM; Tupinambá Branquinho R; de Lana M; Ramos Gadelha F; de Fátima Â
Biomed Pharmacother; 2018 Dec; 108():1703-1711. PubMed ID: 30372873
[TBL] [Abstract][Full Text] [Related]
60. In vitro and in vivo investigation of the efficacy of arylimidamide DB1831 and its mesylated salt form--DB1965--against Trypanosoma cruzi infection.
da Silva CF; Batista Dda G; Oliveira GM; de Souza EM; Hammer ER; da Silva PB; Daliry A; Araujo JS; Britto C; Rodrigues AC; Liu Z; Farahat AA; Kumar A; Boykin DW; Soeiro Mde N
PLoS One; 2012; 7(1):e30356. PubMed ID: 22291940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
